We are translating scientific breakthroughs into therapeutics that can address the symptoms of FSASD and fundamentally alter the course of disease progression
We are establishing powerful new research tools including cell lines, animal models, analytical methods to enable scientists to understand the key drivers behind the disease
We are establishing networks of leading physicians who can conduct clinical studies on patients while supporting studies into the natural history of disease progression
We aim to uncover the many undiagnosed patients living with FSASD while enabling doctors to more rapidly diagnose new cases
The Salla Treatment and Research Foundation (STAR) is delighted to announce the recipients of the 2026 Science Campaign are Dr. May Christine Malicdan and Dr. Raymond Wang. This grant initiative was designed to support the development of gene editing approaches for the treatment of Free Sialic Acid Storage Disorders (FSASDs).
In 2025, thanks to donations from the international STAR community, two projects were funded to support translational research evaluating candidate therapeutics in disease relevant pre-clinical models of Free Sialic AcidStorage Disorder (FSASD). These one year projects will be complete in Fall 2026, with findings shared here.
The FSASD Consortium comprises approximately 40 researchers from over 20 leading institutions around the world dedicated to bringing new therapies to patients with free sialic acid disorders. The Consortium meets quarterly to discuss the latest research breakthroughs and how these can be applied to medicine development.
